Enabling a better product for cancer patients to improve quality of life

We are dedicated to rapidly advancing our key pipeline assets through clinical evaluation with initial focus on metastatic castration-resistant prostate cancer and other solid tumors.


Metastatic Castration-Resistant Prostate Cancer (mCRPC)

mCRPC is an advanced form of prostate cancer and the fourth most common cause of cancer death overall. mCRPC is resistant to surgical treatment or androgen deprivation therapy, an antihormone therapy used to prevent the growth of prostate cancer cells. IV Docetaxel is currently the first-line treatment in this indication in chemotherapy naïve patients. Modra is currently conducting a Phase II clinical trial of Modra006/r in patients with mCRPC.
The following clinical trials of ModraDoc006/r are currently ongoing.


Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Read more

Modra's Novel Approach

Boosted Oral Taxanes    
Learn more


Read more